Last update 20 Mar 2025

RG-6125

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
CDH11
Action
inhibitors
Mechanism
CDH11 inhibitors(Cadherin-11 inhibitors)
Therapeutic Areas
Immune System DiseasesSkin and Musculoskeletal DiseasesNeoplasms+ [1]
Active Indication-
Inactive Indication
NeoplasmsNonalcoholic SteatohepatitisRheumatoid Arthritis
Originator Organization
F. Hoffmann-La Roche Ltd.
Active Organization-
Inactive Organization
F. Hoffmann-La Roche Ltd.Adheron Therapeutics, Inc.Adheron Therapeutics, Inc.
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Related

100 Clinical Results associated with RG-6125
Login to view more data
100 Translational Medicine associated with RG-6125
Login to view more data
100 Patents (Medical) associated with RG-6125
Login to view more data
100 Deals associated with RG-6125
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Rheumatoid ArthritisPhase 2
Italy
F. Hoffmann-La Roche Ltd.
22 Dec 2016
Rheumatoid ArthritisPhase 2
Spain
F. Hoffmann-La Roche Ltd.
22 Dec 2016
Rheumatoid ArthritisPhase 2
Mexico
F. Hoffmann-La Roche Ltd.
22 Dec 2016
Rheumatoid ArthritisPhase 2
Germany
F. Hoffmann-La Roche Ltd.
22 Dec 2016
Rheumatoid ArthritisPhase 2
Austria
F. Hoffmann-La Roche Ltd.
22 Dec 2016
Rheumatoid ArthritisPhase 2
United States
F. Hoffmann-La Roche Ltd.
22 Dec 2016
Rheumatoid ArthritisPhase 2
Colombia
F. Hoffmann-La Roche Ltd.
22 Dec 2016
Rheumatoid ArthritisPhase 2
Argentina
F. Hoffmann-La Roche Ltd.
22 Dec 2016
Rheumatoid ArthritisPhase 2
United Kingdom
F. Hoffmann-La Roche Ltd.
22 Dec 2016
Rheumatoid ArthritisPhase 2
Guatemala
F. Hoffmann-La Roche Ltd.
22 Dec 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
EULAR2019
Phase 2
Rheumatoid Arthritis
anti-TNFα therapy
109
(fnbddmifme) = ggdswwjecn jwxrtryaue (yzebfglubo )
View more
Negative
12 Jun 2019
Placebo
(fnbddmifme) = fakykiynga jwxrtryaue (yzebfglubo )
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free